Dr.Chandana D B

KOL Engagement & Advisory Board Coordination • Supported coordination of Thought Leaders (HCPs, specialists and Researchers) and advisory board engagements by enabling compliance approvals, documentation readiness, and cross‑functional alignment across legal, compliance, and business stakeholders. • Partnered with internal teams to support timely execution of externally facing initiatives while minimizing compliance and inspection risks. Affiliate Engagement and Stakeholder Coordination • Served as primary Point of Contact for the Oncology Business Unit (OBU), managing 300+ tactics and 40+ cross-functional global stakeholders including coordinating affiliate updates and delivery reporting. • Proactively identified project risks and maintained issue logs to ensure stakeholder visibility and timely resolution across multi-disciplinary teams. Vendor & External Partner Management • Oversaw contract agreement management for purchased audiovisual (AV) assets including usage rights, contract expiry monitoring, and renewal coordination — demonstrating vendor engagement and deadline tracking capability. • Led operational execution of Health Education (HE) fulfillment requests, coordinating with external systems and cross-functional teams (GCH/L-MACH, MAE Ops) to ensure timely delivery — reflecting the ability to manage vendor project deliverables end-to-end. Budget Coordination & Financial Tracking • Developed and maintained project‑level trackers in Excel and PowerPoint to support visibility into planned activities, delivery milestones, and potential budget risks during monthly and quarterly stakeholder reviews. • Partnered with finance and business stakeholders to support the validation of project cost data, flag discrepancies (e.g., cost center or scope alignment issues), and ensure trackers accurately reflected execution status.

Review and submission of pharmaceutical promotional/non-promotional materials (print, digital, and video) to VVPM and VVMC, and sharing for MLR review. • Resolved post-review annotations and coordinated revisions until FDA 'Approved for Distribution' status. • Sanofi- Experienced in handling Content localization hub (CLH) projects for different brands of Sanofi. The workflow involves MLR Review, copyediting, and proofreading of promotional materials as per local marketing Regulations, checking the references against AMA guidelines, coordinating with the language and Production team in prepping the localized content, and submission of the approved drafts on “Veeva Vault PromoMats” for client review which involves Reference anchoring, substantiating, and annotating the material and sending them for review. Also, gathering the Post review annotations, resolving the reviewers' comments, by co-0rdinating with creative production and the client whenever required and resubmitting the revised material in the Veeva Platform until it gets “Approved for Distribution” by FDA. • Novartis –Through the Citrix workspace, performing the Quality checks and submissions of all label updates (LUD) and non-LUD Projects and submitting them for initial, functional and validation review in FUSE. Also, Post-review performing Production Proof or gathering AWC (Approved with changes) comments and sending them to the client. • Assist the team in post-RC activity (prepare an annotated document).• Cross-functional collaboration with the brand team and Project Management group to meet both external and internal business needs. • Submission of approved materials on e-platforms (Veeva Vault, Fuse), along with cross-referencing and tagging/linking of claims with articles approved on PubMed. • Managed MLR review, copyediting, and proofreading of promotional materials for Sanofi, Novartis, Pfizer, and Novo Nordisk.

Composed pharmacological and pharmacotherapeutics content scripts per NMC guidelines. • Authored scientific content for company blog and social media platforms. • Copy-edited and proofread scripts from other medical content writers. • Coordinated between medical writers and doctors for final draft approval.

Oncotherapeutics

Score: 72.92%

Score: 88.48%

Score: 71.16%